OptiNose shares are trading lower after the company announced that the FDA extended the review period for the supplemental new drug application of XHANCE by three months.
Portfolio Pulse from Benzinga Newsdesk
OptiNose shares dropped following the announcement that the FDA has extended the review period for the supplemental new drug application of XHANCE by three months.
December 06, 2023 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
OptiNose's stock price is likely to experience a negative impact in the short term due to the FDA's extension of the XHANCE review period.
The FDA's decision to extend the review period of XHANCE is a significant regulatory event for OptiNose, likely causing uncertainty among investors and potentially delaying revenue from the drug. This typically results in a negative short-term reaction in the stock market.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100